Brivaracetam approved for partial-onset seizures by the US-FDA

Written by Alice Weatherston

UCB today announced approval of brivaracetam (BRIVIACT®) by the US-FDA as an adjunctive therapy in the treatment of partial-onset seizures in epilepsy patients aged 16 years and older. The therapy is already available to patients in the UK & Germany for this indication. The approval is based on the results of three Phase III studies, in which BRIVIACT® exhibited efficacy over placebo in reducing partial-onset seizure frequency. Adverse reactions occurred at a frequency of approximately 5% in patients with doses of at least 50mg/day, with nausea, fatigue, dizziness and somnolence being the most common. Discontinuation rates were 5%, 8% &...

To view the full article, please register now for access

It's completely free